Aravive Biologics’ AVB-S6-500 receives FDA fast track designation for ovarian cancer

Aravive Biologics, a biopharmaceutical company, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its novel drug AVB-S6-500, aimed at ... Read More